The Experts below are selected from a list of 59301 Experts worldwide ranked by ideXlab platform
Mahender S Bhist - One of the best experts on this subject based on the ideXlab platform.
-
sodium benzoate in the treatment of acute hepatic encephalopathy a double blind randomized trial
Hepatology, 1992Co-Authors: Sukki Sushma, Satish Jain, Surya Gupta, R K Tandon, Srinivasan Dasarathy, Mahender S BhistAbstract:A prospective randomized double-blind study was conducted to evaluate the efficacy of sodium benzoate in the treatment of acute portal-systemic encephalopathy. Seventy-four consecutive patients with cirrhosis or surgical portasystemic anastamosis and hepatic encephalopathy of less than 7 days duration were randomized to receive lactulose (dose adjusted for 2 or 3 semiformed stools/day) or sodium benzoate (5 gm twice daily). Assessment of response included mental status, asterixis, arterial ammonia level, electroencephalogram and number-connection Test. Each was given a score between 0 and 4+. A portal-systemic encephalopathy index was calculated with these scores. Visual, auditory and somatosensory evoked potentials and a battery of Psychometric Tests for intelligence and memory were also performed to assess improvement. Thirty-eight patients received sodium benzoate; 36 took lactulose. Thirty patients (80%) receiving sodium benzoate and 29 (81%) receiving lactulose recovered; the remaining patients died. Improvement in portal-systemic encephalopathy parameters occurred in both treatment groups and was similar (p > 0.1). Electroencephalogram and evoked potentials were not as helpful as mental status in assessing of recovery. Psychometric Test scores remained abnormal after recovery of mental status (21 to 42 days) and were probably too sensitive for monitoring of these patients. The incidence of side effects was similar in the two treatment groups. The cost of lactulose for one course of therapy was 30 times that of sodium benzoate. We conclude that sodium benzoate is a safe and effective alternative to lactulose in the treatment of acute portasystemic encephalopathy. (HEPATOLOGY 1992;16:138–144.)
-
Sodium benzoate in the treatment of acute hepatic encephalopathy: A double‐blind randomized trial
Hepatology, 1992Co-Authors: Sukki Sushma, Satish Jain, Surya Gupta, R K Tandon, Srinivasan Dasarathy, Mahender S BhistAbstract:A prospective randomized double-blind study was conducted to evaluate the efficacy of sodium benzoate in the treatment of acute portal-systemic encephalopathy. Seventy-four consecutive patients with cirrhosis or surgical portasystemic anastamosis and hepatic encephalopathy of less than 7 days duration were randomized to receive lactulose (dose adjusted for 2 or 3 semiformed stools/day) or sodium benzoate (5 gm twice daily). Assessment of response included mental status, asterixis, arterial ammonia level, electroencephalogram and number-connection Test. Each was given a score between 0 and 4+. A portal-systemic encephalopathy index was calculated with these scores. Visual, auditory and somatosensory evoked potentials and a battery of Psychometric Tests for intelligence and memory were also performed to assess improvement. Thirty-eight patients received sodium benzoate; 36 took lactulose. Thirty patients (80%) receiving sodium benzoate and 29 (81%) receiving lactulose recovered; the remaining patients died. Improvement in portal-systemic encephalopathy parameters occurred in both treatment groups and was similar (p > 0.1). Electroencephalogram and evoked potentials were not as helpful as mental status in assessing of recovery. Psychometric Test scores remained abnormal after recovery of mental status (21 to 42 days) and were probably too sensitive for monitoring of these patients. The incidence of side effects was similar in the two treatment groups. The cost of lactulose for one course of therapy was 30 times that of sodium benzoate. We conclude that sodium benzoate is a safe and effective alternative to lactulose in the treatment of acute portasystemic encephalopathy. (HEPATOLOGY 1992;16:138–144.)
Ivar Roots - One of the best experts on this subject based on the ideXlab platform.
-
Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Trospium Chloride and Placebo on Sleep in Healthy Young Volunteers
Clinical Drug Investigation, 2003Co-Authors: Konstanze Diefenbach, Klaus-dieter Wernecke, Frank Donath, Agathe Maurer, Sabine Quispe Bravo, Jutta Haselmann, Ulrich Schwantes, Ivar RootsAbstract:Objective: Central nervous effects of oral anticholinergics may limit the success of incontinence therapy and patient compliance. Only a few studies investigating this topic are available. This study was conducted to determine whether oral anticholinergics alter sleep and Psychometric Test parameters. Design: Randomised, double-blind, crossover, placebo-controlled study. Study participants: 24 healthy volunteers (age 22–36 years) without sleeprelated problems. Interventions: Polysomnographic recordings, sleep questionnaires and Psychometric Tests (the number combination Test [Zahlen-Verbindungs Test; ZVT] and the d2 attention Test) were performed following single doses of oxybutynin 15mg, tolterodine 4mg, trospium chloride 45mg or placebo, each separated by an 8-day washout period. Results: Rapid eye movement (REM) sleep (relative to total sleep time) was the primary parameter of polysomnography. The REM sleep for oxybutynin was significantly lower than that for trospium chloride (18.4% vs 20.2%; p < 0.05) and lower than that for placebo (20.1%; ns). The number combination Test (ZVT), the primary parameter of cognitive function, and the d2 Test did not reveal any differences in reaction time. With regard to the other sleep parameters, the REM latency for oxybutynin was clearly higher than that for placebo, trospium chloride and tolterodine. Effects on non-REM sleep were observed only after administration of oxybutynin compared with placebo. Conclusions: Oxybutynin influenced sleep structure, as was reflected by REM suppression and mild sedation, while subjective parameters and Psychometric Tests remained unaffected. The sleep and Psychometric Test values for tolterodine and trospium chloride were comparable to those of placebo. The clinical relevance of these effects is small in healthy young volunteers, but these results cannot be extended to the elderly.
-
randomised double blind study of the effects of oxybutynin tolterodine trospium chloride and placebo on sleep in healthy young volunteers
Clinical Drug Investigation, 2003Co-Authors: Konstanze Diefenbach, Klaus-dieter Wernecke, Frank Donath, Agathe Maurer, Sabine Quispe Bravo, Jutta Haselmann, Ulrich Schwantes, Ivar RootsAbstract:Objective: Central nervous effects of oral anticholinergics may limit the success of incontinence therapy and patient compliance. Only a few studies investigating this topic are available. This study was conducted to determine whether oral anticholinergics alter sleep and Psychometric Test parameters.
Sukki Sushma - One of the best experts on this subject based on the ideXlab platform.
-
sodium benzoate in the treatment of acute hepatic encephalopathy a double blind randomized trial
Hepatology, 1992Co-Authors: Sukki Sushma, Satish Jain, Surya Gupta, R K Tandon, Srinivasan Dasarathy, Mahender S BhistAbstract:A prospective randomized double-blind study was conducted to evaluate the efficacy of sodium benzoate in the treatment of acute portal-systemic encephalopathy. Seventy-four consecutive patients with cirrhosis or surgical portasystemic anastamosis and hepatic encephalopathy of less than 7 days duration were randomized to receive lactulose (dose adjusted for 2 or 3 semiformed stools/day) or sodium benzoate (5 gm twice daily). Assessment of response included mental status, asterixis, arterial ammonia level, electroencephalogram and number-connection Test. Each was given a score between 0 and 4+. A portal-systemic encephalopathy index was calculated with these scores. Visual, auditory and somatosensory evoked potentials and a battery of Psychometric Tests for intelligence and memory were also performed to assess improvement. Thirty-eight patients received sodium benzoate; 36 took lactulose. Thirty patients (80%) receiving sodium benzoate and 29 (81%) receiving lactulose recovered; the remaining patients died. Improvement in portal-systemic encephalopathy parameters occurred in both treatment groups and was similar (p > 0.1). Electroencephalogram and evoked potentials were not as helpful as mental status in assessing of recovery. Psychometric Test scores remained abnormal after recovery of mental status (21 to 42 days) and were probably too sensitive for monitoring of these patients. The incidence of side effects was similar in the two treatment groups. The cost of lactulose for one course of therapy was 30 times that of sodium benzoate. We conclude that sodium benzoate is a safe and effective alternative to lactulose in the treatment of acute portasystemic encephalopathy. (HEPATOLOGY 1992;16:138–144.)
-
Sodium benzoate in the treatment of acute hepatic encephalopathy: A double‐blind randomized trial
Hepatology, 1992Co-Authors: Sukki Sushma, Satish Jain, Surya Gupta, R K Tandon, Srinivasan Dasarathy, Mahender S BhistAbstract:A prospective randomized double-blind study was conducted to evaluate the efficacy of sodium benzoate in the treatment of acute portal-systemic encephalopathy. Seventy-four consecutive patients with cirrhosis or surgical portasystemic anastamosis and hepatic encephalopathy of less than 7 days duration were randomized to receive lactulose (dose adjusted for 2 or 3 semiformed stools/day) or sodium benzoate (5 gm twice daily). Assessment of response included mental status, asterixis, arterial ammonia level, electroencephalogram and number-connection Test. Each was given a score between 0 and 4+. A portal-systemic encephalopathy index was calculated with these scores. Visual, auditory and somatosensory evoked potentials and a battery of Psychometric Tests for intelligence and memory were also performed to assess improvement. Thirty-eight patients received sodium benzoate; 36 took lactulose. Thirty patients (80%) receiving sodium benzoate and 29 (81%) receiving lactulose recovered; the remaining patients died. Improvement in portal-systemic encephalopathy parameters occurred in both treatment groups and was similar (p > 0.1). Electroencephalogram and evoked potentials were not as helpful as mental status in assessing of recovery. Psychometric Test scores remained abnormal after recovery of mental status (21 to 42 days) and were probably too sensitive for monitoring of these patients. The incidence of side effects was similar in the two treatment groups. The cost of lactulose for one course of therapy was 30 times that of sodium benzoate. We conclude that sodium benzoate is a safe and effective alternative to lactulose in the treatment of acute portasystemic encephalopathy. (HEPATOLOGY 1992;16:138–144.)
Susanne S. Pedersen - One of the best experts on this subject based on the ideXlab platform.
-
one year results of the randomized controlled short term psychotherapy in acute myocardial infarction step in ami trial
International Journal of Cardiology, 2013Co-Authors: Adriana Roncella, Cinzia Cianfrocca, Vincenzo Pasceri, Francesco Pelliccia, Johan Denollet, Susanne S. Pedersen, Christian Pristipino, Silvia ScorzaAbstract:Abstract Background Previous studies on cognitive and interpersonal interventions have yielded inconsistent results in ischemic heart disease patients. Methods 101 patients aged ≤70years, and enrolled one week after complete revascularization with urgent/emergent angioplasty for an AMI, were randomized to standard cardiological therapy plus short-term humanistic–existential psychotherapy (STP) versus standard cardiological therapy only. Primary composite end point was: one-year incidence of new cardiological events (re-infarction, death, stroke, revascularization, life-threatening ventricular arrhythmias, and the recurrence of typical and clinically significant angina) and of clinically significant new comorbidities. Secondary end points were: rates for individual components of the primary outcome, incidence of re-hospitalizations for cardiological problems, New York Heart Association class, and Psychometric Test scores at follow-up. Results 94 patients were analyzed at one year. The two treatment groups were similar across all baseline characteristics. At follow-up, STP patients had had a lower incidence of the primary endpoint, relative to controls (21/49 vs. 35/45 patients; p=0.0006, respectively; NNT=3); this benefit was attributable to the lower incidence of recurrent angina and of new comorbidities in the STP group (14/49 vs. 22/45 patients, p=0.04, NNT=5; and 5/49 vs. 25/45, p Conclusion Adding STP to cardiological therapy improves cardiological symptoms, quality of life, and psychological and medical outcomes one year post AMI, while reducing the need for re-hospitalizations. Larger studies remain necessary to confirm the generalizability of these results. Clinical trial registration ClinicalTrial.gov: NCT00769366
Satish Jain - One of the best experts on this subject based on the ideXlab platform.
-
sodium benzoate in the treatment of acute hepatic encephalopathy a double blind randomized trial
Hepatology, 1992Co-Authors: Sukki Sushma, Satish Jain, Surya Gupta, R K Tandon, Srinivasan Dasarathy, Mahender S BhistAbstract:A prospective randomized double-blind study was conducted to evaluate the efficacy of sodium benzoate in the treatment of acute portal-systemic encephalopathy. Seventy-four consecutive patients with cirrhosis or surgical portasystemic anastamosis and hepatic encephalopathy of less than 7 days duration were randomized to receive lactulose (dose adjusted for 2 or 3 semiformed stools/day) or sodium benzoate (5 gm twice daily). Assessment of response included mental status, asterixis, arterial ammonia level, electroencephalogram and number-connection Test. Each was given a score between 0 and 4+. A portal-systemic encephalopathy index was calculated with these scores. Visual, auditory and somatosensory evoked potentials and a battery of Psychometric Tests for intelligence and memory were also performed to assess improvement. Thirty-eight patients received sodium benzoate; 36 took lactulose. Thirty patients (80%) receiving sodium benzoate and 29 (81%) receiving lactulose recovered; the remaining patients died. Improvement in portal-systemic encephalopathy parameters occurred in both treatment groups and was similar (p > 0.1). Electroencephalogram and evoked potentials were not as helpful as mental status in assessing of recovery. Psychometric Test scores remained abnormal after recovery of mental status (21 to 42 days) and were probably too sensitive for monitoring of these patients. The incidence of side effects was similar in the two treatment groups. The cost of lactulose for one course of therapy was 30 times that of sodium benzoate. We conclude that sodium benzoate is a safe and effective alternative to lactulose in the treatment of acute portasystemic encephalopathy. (HEPATOLOGY 1992;16:138–144.)
-
Sodium benzoate in the treatment of acute hepatic encephalopathy: A double‐blind randomized trial
Hepatology, 1992Co-Authors: Sukki Sushma, Satish Jain, Surya Gupta, R K Tandon, Srinivasan Dasarathy, Mahender S BhistAbstract:A prospective randomized double-blind study was conducted to evaluate the efficacy of sodium benzoate in the treatment of acute portal-systemic encephalopathy. Seventy-four consecutive patients with cirrhosis or surgical portasystemic anastamosis and hepatic encephalopathy of less than 7 days duration were randomized to receive lactulose (dose adjusted for 2 or 3 semiformed stools/day) or sodium benzoate (5 gm twice daily). Assessment of response included mental status, asterixis, arterial ammonia level, electroencephalogram and number-connection Test. Each was given a score between 0 and 4+. A portal-systemic encephalopathy index was calculated with these scores. Visual, auditory and somatosensory evoked potentials and a battery of Psychometric Tests for intelligence and memory were also performed to assess improvement. Thirty-eight patients received sodium benzoate; 36 took lactulose. Thirty patients (80%) receiving sodium benzoate and 29 (81%) receiving lactulose recovered; the remaining patients died. Improvement in portal-systemic encephalopathy parameters occurred in both treatment groups and was similar (p > 0.1). Electroencephalogram and evoked potentials were not as helpful as mental status in assessing of recovery. Psychometric Test scores remained abnormal after recovery of mental status (21 to 42 days) and were probably too sensitive for monitoring of these patients. The incidence of side effects was similar in the two treatment groups. The cost of lactulose for one course of therapy was 30 times that of sodium benzoate. We conclude that sodium benzoate is a safe and effective alternative to lactulose in the treatment of acute portasystemic encephalopathy. (HEPATOLOGY 1992;16:138–144.)
